324813
Soluble Epoxide Hydrolase Inhibitor, NCND
The Soluble Epoxide Hydrolase Inhibitor, NCND, also referenced under CAS 402939-18-8, controls the biological activity of Soluble Epoxide Hydrolase.
別名:
Soluble Epoxide Hydrolase Inhibitor, NCND, CDU, N-Cyclohexyl-Nʹ-dodecylurea, 1-Cyclohexyl-3ʹ-dodecylurea
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C19H38N2O
CAS番号:
分子量:
310.52
MDL number:
UNSPSC Code:
12352202
NACRES:
NA.54
Assay:
≥95% (TLC)
Form:
solid
Storage condition:
OK to freeze
Quality Segment
assay
≥95% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
dichloromethane: 1 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
N(C1CCCCC1)C(=O)NCCCCCCCCCCCC
InChI
1S/C19H38N2O/c1-2-3-4-5-6-7-8-9-10-14-17-20-19(22)21-18-15-12-11-13-16-18/h18H,2-17H2,1H3,(H2,20,21,22)
InChI key
POEWFBSYPFIYSK-UHFFFAOYSA-N
General description
A cell-permeable 1,3-disubstituted urea compound that displays anti-hypertensive and anti-inflammatory properties. Acts as a potent, selective, competitive, and tight-binding transition-state analog inhibitor of soluble epoxide hydrolase (sEH; IC50 = 9.8 nM for mouse recombinant sEH, 85.2 nM for human recombinant sEH). Reported to decrease human VSMC (vascular smooth muscle cell) proliferation.
A cell-permeable, potent, selective, competitive, and tight binding transition-state analog inhibitor of soluble epoxide hydrolase (sEH) (IC50 = 9.8 nM for recombinant murine sEH and 85.2 nM for recombinant human sEH). Also displays anti-hypertensive and anti-inflammatory properties. Reported to decrease human vascular smmoth muscle cell (VSMC) proliferation.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Soluble epoxide hydrolase
Soluble epoxide hydrolase
Product competes with ATP.
Reversible: no
Target IC50: 9.8 nM for mouse recombinant sEH, 85.2 nM for human recombinant sEH
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Newman, J.W., et al. 2003. Proc. Natl. Acad. Sci. USA100, 1558.
Davis, B.B., et al. 2002. Proc. Natl. Acad. Sci. USA99, 2222.
Morisseau, C., et al. 2002. Biochem. Pharmacol.63, 1599.
Imig, J.D., et al. 2002. Hypertension39, 690.
Argiriadi, M.A., et al. 2000. J. Biol. Chem.275, 15265.
Yu, Z., et al. 2000. Circ. Res.87, 992.
Davis, B.B., et al. 2002. Proc. Natl. Acad. Sci. USA99, 2222.
Morisseau, C., et al. 2002. Biochem. Pharmacol.63, 1599.
Imig, J.D., et al. 2002. Hypertension39, 690.
Argiriadi, M.A., et al. 2000. J. Biol. Chem.275, 15265.
Yu, Z., et al. 2000. Circ. Res.87, 992.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
324813-25MG: + 324813-5UNMG: + 324813-MG: + 324813-175MG:
jan